Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.

[1]  K. Song,et al.  Epigenetic Silencing of miRNA-34a in Human Cholangiocarcinoma via EZH2 and DNA Methylation: Impact on Regulation of Notch Pathway. , 2017, The American journal of pathology.

[2]  Feng Zhu,et al.  The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A , 2016, Cancer Chemotherapy and Pharmacology.

[3]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[4]  Jie Sun,et al.  MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2 , 2015, Journal of Neuro-Oncology.

[5]  Y. Toiyama,et al.  Vasohibin-1 increases the malignant potential of colorectal cancer and is a biomarker of poor prognosis. , 2014, Anticancer research.

[6]  G. Angelini,et al.  EZH2 Modulates Angiogenesis In Vitro and in a Mouse Model of Limb Ischemia , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Feipeng Zhao,et al.  EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma , 2014, Oncotarget.

[8]  M. Hirota,et al.  EZH2 Is Associated with Malignant Behavior in Pancreatic IPMN via p27Kip1 Downregulation , 2014, PloS one.

[9]  Xiaoming Hou,et al.  Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer , 2014, Medical Oncology.

[10]  M. Kurokawa,et al.  Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16 , 2014, Cancer science.

[11]  T. H. Klotz,et al.  Prospective randomized double‐blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO‐AB 31/05) , 2014, BJU international.

[12]  Y. Sakamoto,et al.  Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells. , 2014, Oncology reports.

[13]  Shan Wang,et al.  A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1 , 2014, Medical Oncology.

[14]  H. Lenz,et al.  S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma , 2014, British Journal of Cancer.

[15]  G. Abou-Alfa,et al.  A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas , 2013, British Journal of Cancer.

[16]  Y. Sakamoto,et al.  Enhancer of Zeste Homolog 2 (EZH2) Promotes Progression of Cholangiocarcinoma Cells by Regulating Cell Cycle and Apoptosis , 2013, Annals of Surgical Oncology.

[17]  P. Saharinen,et al.  Angiopoietin signaling in the vasculature. , 2013, Experimental cell research.

[18]  D. Grimm,et al.  Biomarkers for Anti-Angiogenic Therapy in Cancer , 2013, International journal of molecular sciences.

[19]  Y. Okada,et al.  The prognostic significance of vasohibin-1 expression in patients with prostate cancer , 2013, British Journal of Cancer.

[20]  L. Claesson‐Welsh,et al.  VEGFA and tumour angiogenesis , 2013, Journal of internal medicine.

[21]  K. Plate,et al.  Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited , 2012, Acta Neuropathologica.

[22]  H. Ji,et al.  Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis , 2012, Proceedings of the National Academy of Sciences.

[23]  Yan Sun,et al.  Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma , 2012, Medical Oncology.

[24]  Y. Sakamoto,et al.  Carcinogenesis of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2 , 2012, Annals of Surgical Oncology.

[25]  Y. Kubota,et al.  Tumor angiogenesis and anti-angiogenic therapy. , 2012, The Keio journal of medicine.

[26]  F. Crea,et al.  EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis , 2012, Cancer and Metastasis Reviews.

[27]  A. Zhu,et al.  Targeted therapy for biliary tract cancers , 2012, Journal of hepato-biliary-pancreatic sciences.

[28]  L. Schwartz,et al.  Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results , 2011, Oncology.

[29]  M. Sabel,et al.  EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development , 2011, Modern Pathology.

[30]  T. Ishiko,et al.  Hepatic Stellate Cells Accelerate the Malignant Behavior of Cholangiocarcinoma Cells , 2011, Annals of Surgical Oncology.

[31]  H. Sasano,et al.  Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas , 2011, Cancer science.

[32]  Robert Brown,et al.  Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2 , 2011, Molecular Cancer Therapeutics.

[33]  Jing Wang,et al.  Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo , 2010, Cancer biology & therapy.

[34]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[35]  H. Sasano,et al.  Vasohibin‐1 as a potential predictor of aggressive behavior of ductal carcinoma in situ of the breast , 2010, Cancer science.

[36]  H. Sugiyama,et al.  Vasohibin-1, a Negative Feedback Regulator of Angiogenesis, Ameliorates Renal Alterations in a Mouse Model of Diabetic Nephropathy , 2009, Diabetes.

[37]  H. Sasano,et al.  Vasohibin‐1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis , 2009, Cancer science.

[38]  Yasufumi Sato,et al.  Multiple processing forms and their biological activities of a novel angiogenesis inhibitor vasohibin. , 2006, Biochemical and biophysical research communications.

[39]  P. Campochiaro,et al.  Vasohibin is up‐regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  M. Abe,et al.  Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. , 2004, The Journal of clinical investigation.

[41]  N. LaRusso,et al.  The Pathophysiology of Biliary Epithelia , 2004 .

[42]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[44]  N. LaRusso,et al.  The pathobiology of biliary epithelia , 2002, Hepatology.

[45]  A. Weaver,et al.  "Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. , 1995, Mayo Clinic proceedings.

[46]  M. Thomas.  Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. , 2007, Critical reviews in oncology/hematology.